Ever since Philip S Hench was awarded the Nobel Prize in Physiology or Medicine in 1950 for introducing glucocorticoids into clinical medicine, its mode of action and its application in the treatment of rheumatic diseases continues to be studied. Articles in this supplement look at what we have learned about the use of glucocorticoids in rheumatic diseases, and how insulin resistance, common in chronic inflammatory systemic diseases, serves as an example to demonstrate the complex crosstalk of the endocrine, nervous and immune systems.
Volume 16 Supplement 2
At the interface between immunology and endocrinology in rheumatic diseases
Reviews
Edited by Rainer Straub
This supplement was proposed, developed and commissioned by Arthritis Research & Therapy and was funded by an educational grant from Horizon Pharma Inc. All published articles were independently prepared by the authors and have undergone peer review in accordance with the journal’s standard policies and processes. Horizon Pharma Inc had no input into the topics covered or the articles themselves. The Supplement Editor was appointed by the journal and declares that they have no competing interests.
Follow
Annual Journal Metrics
-
2022 Citation Impact
4.9 - 2-year Impact Factor
5.7 - 5-year Impact Factor
1.501 - SNIP (Source Normalized Impact per Paper)
1.592 - SJR (SCImago Journal Rank)2023 Speed
11 days submission to first editorial decision for all manuscripts (Median)
111 days submission to accept (Median)2023 Usage
3,331,819 downloads
1,885 Altmetric mentions